Core Viewpoint - Gyre Therapeutics has received priority review status from China's NMPA for its New Drug Application for Hydronidone (F351), aimed at treating chronic hepatitis B-induced liver fibrosis, marking a significant milestone in the drug approval process [1][2]. Group 1: Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, focusing on innovative treatments for liver fibrosis, with operations in both the United States and China [1][8]. - The company holds a 69.7% equity interest in Gyre Pharmaceuticals, which is responsible for the development and commercialization of Hydronidone [7]. Group 2: Drug Information - Hydronidone (F351) is an orally administered anti-fibrotic agent that targets liver fibrosis pathways by inhibiting TGF-β1-induced signaling, which is crucial for fibrogenesis [4]. - The drug has completed Phase 3 clinical trials in China for chronic hepatitis B-associated liver fibrosis, including cases of early compensated cirrhosis [5]. Group 3: Market Context - Chronic hepatitis B (CHB) affects approximately 254 million people globally, with a significant number developing liver fibrosis and cirrhosis, highlighting the urgent medical need for effective treatments [6]. - The prevalence of CHB is particularly high in China and the United States, making the approval of Hydronidone potentially impactful for millions of patients [6]. Group 4: Regulatory Insights - The priority review designation by the NMPA was established to expedite the drug registration process for new drugs with significant clinical value, allowing for a faster review and allocation of resources [3].